Craig Heneghan, Senior Advisor and Board Member of Argentum Pharmaceuticals, explains just how important it is for the United States to reshore generic drug manufacturing: “If we were sourcing a drug outside the U.S., that was a single source pharmaceutical. And that country, for whatever reason, halted the shipment of that product…. In 8 to 16 weeks we would be out of stock of that product.”